Unichem Labs gets USFDA nod to market Allopurinol tablets

Allopurinol tablets will be commercialised from company's Ghaziabad plant, Unichem Laboratories said.

New Delhi: Drug firm Unichem Laboratories Wednesday said it has received approval from the US health regulator to market its Allopurinol tablets.

The company has received approval from the United States Food and Drug Administration (USFDA) to market generic Allopurinol tablets in the strengths of 100 mg and 300 mg, Unichem Laboratories said in a filing to BSE.

Read Also: Unichem Labs Ghaziabad facility successfully completes USFDA inspection

The tablets are the generic version of Zyloprim tablets, it added.

The product will be commercialised from company's Ghaziabad plant, Unichem Laboratories said.

The tablets are indicated for the management of patients with signs and symptoms of primary or secondary gout and those with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels among others.

Read Also: Unichem Labs standalone net profit declines 99.83 percent in Q3

Unichem Laboratories is one of India's oldest pharmaceutical company headquartered in Mumbai, Maharashtra. The company's main interest is in synthesis, development, manufacturing, marketing and export of bulk drugs, chemical intermediates and formulations, serving the needs of both human and veterinary health-care.